Polycystic Ovary Syndrome (PCOS) - 5-10% of women 50% lower glutathione levels compared to women without PCOS 3-4x higher risk of preeclampsia 3x higher risk of gestational diabetes Critical concern: With 50% lower baseline glutathione, the "safe" dose is effectively cut in half IVF Conception - 2-5% of births (up to 6-8% in some countries) Women who conceive via IVF experience dramatic antioxidant depletion: 70% reduction in plasma antioxidant capacity 83% reduction in follicular fluid antioxidant capacity 50-100%+ increase in oxidative stress markers With over 5 million babies born via IVF globally, this represents a large high-risk population Gallbladder Dysfunction - 10% of pregnant women Up to 10% develop gallstones or biliary sludge Intrahepatic cholestasis: 0.4-10% of pregnancies CRITICAL: Fatal Outcomes Documented at Therapeutic Doses The first case of a pregnant woman with intrahepatic cholestasis who died from liver failure after taking THERAPEUTIC/NORMAL doses of acetaminophen was reported in 2022
However, younger adults are not safe, and B12 deficiency can result from stress, poor nutrition and certain medications like antacids or diabetes drugs
The safety of compounded semaglutide is hard to guarantee
Glaucoma and Vision Loss: Studies found that patients on GLP-1 drugs had a lower risk of glaucoma -related vision loss
Understanding GLP-1 Medications What Are GLP-1 Medications
Most patients report initial nausea between 1 and 3 hours after their weekly injection, with symptoms ranging from mild queasiness to moderate discomfort
